Hiroaki Ikezaki
- Hepatology top 5%
- Hepatitis C virus research 16
-
- Diabetes, Cardiovascular Risks, and Lipoproteins 14
- Epidemiology top 10%
- Hepatitis B Virus Studies 11
- Liver Disease Diagnosis and Treatment 10
-
- Cardiovascular Health and Disease Prevention 6
-
- Lipoproteins and Cardiovascular Health 12
- Helicobacter pylori-related gastroenterology studies 5
-
- SARS-CoV-2 and COVID-19 Research 4
- Co-authors
- Norihiro FurusyoErnst J. SchaeferJun HayashiMasayuki MurataTakuji KohzumaChing‐Ti LiuEiichi OgawaBela F. Asztalos
- Partner nations
- JapanUnited StatesNetherlands
In The Last Decade
Hiroaki Ikezaki
52 papers receiving 877 citations
Peers
Comparison fields: 5 of 81
- Hepatology 172
- Endocrinology, Diabetes and Metabolism 351
- Epidemiology 269
- Cardiology and Cardiovascular Medicine 151
- Surgery 263
Countries citing papers authored by Hiroaki Ikezaki
This map shows the geographic impact of Hiroaki Ikezaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Ikezaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Ikezaki more than expected).
Fields of papers citing papers by Hiroaki Ikezaki
This network shows the impact of papers produced by Hiroaki Ikezaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Ikezaki. The network helps show where Hiroaki Ikezaki may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hiroaki Ikezaki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 0 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 4 | |
| 7 | 2022 | 24 | |
| 8 | 2022 | 3 | |
| 9 | 2021 | 3 | |
| 10 | 2019 | 2 | |
| 11 | 2017 | 22 | |
| 12 | 2016 | 3 | |
| 13 | 2015 | 3 | |
| 14 | 2014 | 33 | |
| 15 | 2014 | 2 | |
| 16 | 2013 | 24 | |
| 17 | 2012 | 36 | |
| 18 | 2011 | 4 | |
| 19 | 2011 | 120 | |
| 20 | 2011 | 13 |
About Hiroaki Ikezaki
Hiroaki Ikezaki is a scholar working on Hepatology, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine, having authored 56 papers that have together received 882 indexed citations. Recurring topics across this work include Hepatitis C virus research (16 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (14 papers), Lipoproteins and Cardiovascular Health (12 papers), Hepatitis B Virus Studies (11 papers), Liver Disease Diagnosis and Treatment (10 papers), Cardiovascular Health and Disease Prevention (6 papers), Helicobacter pylori-related gastroenterology studies (5 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). The work is most often cited by research in Hepatology (172 citations), Endocrinology, Diabetes and Metabolism (351 citations) and Epidemiology (269 citations). Hiroaki Ikezaki has collaborated with scholars based in Japan, United States and Netherlands. Frequent co-authors include Norihiro Furusyo, Ernst J. Schaefer, Jun Hayashi, Masayuki Murata, Takuji Kohzuma, Ching‐Ti Liu, Eiichi Ogawa, Bela F. Asztalos, Kazuhiro Toyoda and Takeshi Ihara.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.